Close Menu

Cowen & Co.

NEW YORK (GenomeWeb News) – Citing a recent run up in Life Technologies' stock fueled by speculation that it may be positioning itself to be bought, investment bank Cowen & Co. today downgraded the Carlsbad, Calif.-based firm to Neutral from Outperform.

NEW YORK (GenomeWeb News) – Investment bank Cowen and Co. has downgraded the stocks of Luminex and Qiagen to Underperform from Neutral.

NEW YORK (GenomeWeb News) – Piper Jaffray today downgraded Cepheid to a Neutral rating from Overweight, saying a manufacturing issue related to its Xpert cartridges could negatively impact fourth-quarter revenues.

Fluidigm first disclosed its renewed IPO effort in early December, reviving plans for a public offering that the company put on hiatus in September 2008 amid the economic downturn.

The vendors hope to help customers obtain funding from a new program called NIH Challenge Grants, which will set aside between $100 million and $200 million, and the National Centers for Research Resources, which will get an additional $300 million.

Nanogen's full-year revenues rose 23 percent, but the firm's cash holdings has fallen to nearly $3 million, which is not enough funding to support its plans for 2009.

Pages

Researchers tie a variant in ADAMTS3 to breathing difficulties in dissimilar dog breeds, according to Discover's D-brief blog.

The Japan Times reports that researchers sequenced the genome of a woman who lived during the Jomon period.

Parents of children with rare genetic disease have to contend with shifts in the interpretation of genetic variants, the Wall Street Journal reports.

In Science this week: single-nucleus RNA sequencing of brain tissue from individuals with autism, and more.